Study backs T-wave alternans test:
This article was originally published in Clinica
Measuring T-wave alternans, subtle beat-to-beat fluctuations in heartbeat, could help predict ventricular tachycardia (VT) in patients with non-ischaemic dilated cardiomyopathy (DCM), according to a study published in the Journal of the American College of Cardiology (August). The sensitivity, specificity and predictive accuracy of T-wave alternans for VT in 58 patients with DCM were 88%, 72% and 77% respectively. US company Cambridge Heart of Bedford, Massachusetts, which makes the only non-invasive T-wave alternans test with FDA clearance, said the findings were significant since a conventional electrophysiology study is not considered useful in diagnosing patients with non-ischaemic DCM.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.